Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.37 |
| ▸ | HTR3B | O95264 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836969 | 0.80 | HTR3E (0.62) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL641405 | 0.78 | IDO1 (0.44) | IDO1 | |
| SCHEMBL23578294 | 0.78 | MEP1B (0.31) | — | |
| SCHEMBL836980 | 0.74 | IDO1 (0.47) | IDO1TSHR | |
| SCHEMBL15018565 | 0.72 | IDO1 (0.39) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29844260 | 0.71 | MEN1 (0.41) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL15018609 | 0.71 | IDO1 (0.41) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29844275 | 0.70 | ALDH1A1 (0.39) | — | |
| SCHEMBL836580 | 0.69 | MAPK8 (0.39) | IDO1 | |
| SCHEMBL434982 | 0.68 | HDAC8 (0.56) | IDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| EP-2272848-A1 | Xanthine derivatives as selective HM74A agonists | Glaxosmithkline LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | HTR3E 569/4885HTR3B 162/4885HTR3A 182/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | HTR3E 401/4885HTR3B 125/4885HTR3A 155/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | HTR3E 745/4885HTR3B 212/4885HTR3A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.